Individualized Treatment of Type 2 Diabetes Mellitus Using Noninsulin Agents: Clinical Considerations for the Primary Care Physician

References

• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Schernthaner G, Barnett AH, Betteridge DJ, . Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53(7):1258–1269
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–549
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care. 1999;22(1):33–37
   PubMedGoogle Scholar
• . DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27(3):309–317
   PubMed Web of Science ®Google Scholar
• . Bennett WL, Maruthur NM, Singh S, . Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011; 154(9):602–613
   PubMed Web of Science ®Google Scholar
• . Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;79(2):196–203
   PubMed Web of Science ®Google Scholar
• . Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010; 303(14):1410–1418
   PubMed Web of Science ®Google Scholar
• . Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001. Diabetes Care. 2003;26(6):1852–1855
   PubMed Web of Science ®Google Scholar
• . Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26(6):1847–1851
   PubMed Web of Science ®Google Scholar
• . Kalsekar I, Sheehan C, Peak A. Utilization patterns and medication adherence in patients with type 2 diabetes: variations based on type of pharmacy (chain vs independent). Res Social Adm Pharm. 2007;3(4):378–391
   PubMedGoogle Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6): 540–559
   PubMed Web of Science ®Google Scholar
• . Saenz A, Fernandez—Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(3):CD002966
   Google Scholar
• . Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(2):CD003639
   Google Scholar
• . Norris SL, Carson S, Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr Diabetes Rev. 2007;3(2):127–140
   PubMedGoogle Scholar
• . Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909–917
   PubMed Web of Science ®Google Scholar
• . Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86(1):44–57
   PubMed Web of Science ®Google Scholar
• . Richter B, Bandeira—Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;(2):CD006739
   Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Chapell R, Gould AL, Alexander CM. Baseline differences in A1c explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab. 2009;11(11):1009–1016
   PubMed Web of Science ®Google Scholar
• . Handelsman Y, Mechanick JI, Blonde L, ; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17( suppl 2):S1–S53
   PubMedGoogle Scholar
• . Chen CT, Chen W, Chung HH, Cheng KC, Yeh CH, Cheng JT. Activation of imidazoline I-2B receptor by metformin to increase glucose uptake in skeletal muscle. Horm Metab Res. 2011;43(10):708–713
   PubMedGoogle Scholar
• . Magalhães FO, Gouveia LM, Torquato MT, Paccola GM, Piccinato CE, Foss MC. Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients. Horm Metab Res. 2006;38(8):513–517
   PubMedGoogle Scholar
• . Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia. 2006;49(3):434–441
   PubMed Web of Science ®Google Scholar
• . Jackson RA, Hawa MI, Jaspan JB, . Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes. 1987;36(5):632–640
   PubMedGoogle Scholar
• . Johnson AB, Webster JM, Sum CF, . The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism. 1993;42(9):1217–1222
   PubMedGoogle Scholar
• . www.Drugs.com. Professional Drug Information database. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed September 13, 2011
   Google Scholar
• . Glucophage (metformin HCl) prescribing information. http://www.accessdata.fda.gov. Updated 2008. Accessed October 24, 2011
   Google Scholar
• . Perriello G, Misericordia P, Volpi E, . Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994;43(7):920–928
   PubMedGoogle Scholar
• . Lehmann JM, Moore LB, Smith—Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270(22):12953–12956
   PubMed Web of Science ®Google Scholar
• . Mukherjee R, Davies PJ, Crombie DL, . Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997;386(6623):407–410
   PubMed Web of Science ®Google Scholar
• . Sears DD, Hsiao G, Hsiao A, . Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci USA. 2009;106(44):18745–18750
   PubMedGoogle Scholar
• . Miyazaki Y, Mahankali A, Matsuda M, . Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87(6):2784–2791
   PubMed Web of Science ®Google Scholar
• . Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25(3):517–523
   PubMed Web of Science ®Google Scholar
• . Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1999;1(3):165–172
   PubMed Web of Science ®Google Scholar
• . Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43(3):278–284
   PubMed Web of Science ®Google Scholar
• . Glass LC, Cusi K, Berria R, . Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with type 2 diabetes: a double tracer OGTT study. Clin Endocrinol (Oxf). 2010;73(3):339–345
   PubMedGoogle Scholar
• . Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011
   Google Scholar
• . Actos [package insert]. Deerfield, IL: Takeda Pharmaceuticals; 2012
   Google Scholar
• . Chappuis B, Braun M, Stettler C, . Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev. 2007;23(5):392–399
   PubMed Web of Science ®Google Scholar
• . Varanasi A, Bellini N, Rawal D, . Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165(1):77–84
   PubMed Web of Science ®Google Scholar
• . Raman VS, Mason KJ, Rodriguez LM, . The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33(6):1294–1296
   PubMed Web of Science ®Google Scholar
• . www.Drugs.com. Precose (acarbose) prescribing information 2008. http://www.accessdata.fda.gov. Updated November 2011. Accessed March 23, 2011
   Google Scholar
• . Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 ( suppl 2):S14–S21
   PubMed Web of Science ®Google Scholar
• . Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol. 2002;156(8):714–719
   PubMed Web of Science ®Google Scholar
• . Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–228
   PubMed Web of Science ®Google Scholar
• . Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191–1201
   PubMed Web of Science ®Google Scholar
• . Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22
   PubMed Web of Science ®Google Scholar
• . Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224–235
   PubMed Web of Science ®Google Scholar
• . Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389–394
   PubMed Web of Science ®Google Scholar
• . Tzoulaki I, Molokhia M, Curcin V, . Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• . Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6
   PubMed Web of Science ®Google Scholar
• . Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3
   PubMed Web of Science ®Google Scholar
• . Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362–372
   PubMed Web of Science ®Google Scholar
• . Monami M, Cremasco F, Lamanna C, . Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764
   PubMedGoogle Scholar
• . Nauck M, Frid A, Hermansen K, ; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010;23(3):334–339
   PubMed Web of Science ®Google Scholar
• . Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29(1):14–25
   PubMedGoogle Scholar
• . Gaziano JM, Cincotta AH, O'Connor CM, . Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33(7):1503–1508
   PubMed Web of Science ®Google Scholar
• . www.ClinicalTrials.gov. The Metformin in Coronary Artery Bypass Graft (CABG) (MetCAB) Trial. http://www.clinicaltrials.gov/ct2/show/NCT01438723?term=NCT01438723&rank=1. Accessed June 1, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Metformin to Reduce Heart Failure After Myocardial Infarction (GIPS-III). http://www.clinicaltrials.gov/ct2/show/NCT01217307?term=NCT01217307&rank=1. Accessed June 1, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial (TOSCA IT). http://www.clinicaltrials.gov/ct2/show/NCT00700856?term=NCT00700856.&rank=1. Accessed June 1, 2012
   Google Scholar
• . www.ClinicalTrials.gov. The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT) (PIONEER). http://www.clinicaltrials.gov/ct2/show/NCT01341730?term=NCT01341730&rank=1. Accessed June 12, 2012
   Google Scholar
• . www.ClinicalTrials.gov. PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease (RA PPAR). http://www.clinicaltrials.gov/ct2/show/NCT00554853?term=NCT00554853&rank=1. Accessed June 12, 2012
   Google Scholar
• . www.ClinicalTrials.gov. The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT). http://www.clinicaltrials.gov/ct2/show/NCT01331967?term=NCT01331967&rank=1. Accessed June 1, 2012
   Google Scholar
• . Scottish Intercollegiate Guidelines Network. Management of diabetes. A national clinical guideline. 2010. http://www.sign.ac.uk/pdf/sign116.pdf. Acccessed March 15, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Effects of exenatide in type 2 diabetic patients with congestive heart failure. http://clinicaltrials.gov/ct2/show/NCT00766857. Accessed April 24, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Effect of additional treatment with EXenatide in patients with an acute myocardial infarction (the EXAMI Trial). http://clinicaltrials.gov/ct2/show/NCT01254123. Accessed April 24, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Evaluating the use of exenatide in people with type 2 diabetes and diastolic heart failure. http://clinicaltrials.gov/ct2/show/NCT00799435. Accessed April 24, 2012
   Google Scholar
• . www.ClinicalTrials.gov. GLP-1 agonist exenatide for improved glucose control and cardiac function in diabetic patients with aortocoronary bypass (executive). http://clinicaltrials.gov/ct2/show/NCT01373216. Accessed April 24, 2012
   Google Scholar
• . www.ClinicalTrials.gov. The study of exenatide action on vessel function in type 2 diabetes and prediabetes. http://clinicaltrials.gov/ct2/show/NCT01181986. Accessed April 24, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Impact of liraglutide on endothelial function and microvascular blood flow in type 2 diabetes mellitus. http://clinicaltrials.gov/ct2/show/NCT01181986. Accessed April 23, 2012
   Google Scholar
• . Rendell M, Chrysant SG, Emser A, . Linagliptin effectively reduces HbA1c independent of gender in patients with type 2 diabetes. Presented at: Endocrine Society 93rd Annual Meeting; June 4–7, 2011; Boston, MA
   Google Scholar
• . Ryden L, Standl E, Bartnik M, ; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136
   PubMed Web of Science ®Google Scholar
• . Trujillo A, Rendell M, Chrysant SG, . Linagliptin improves glycemic control independent of body mass index in patients with type 2 diabetes. Presented at: American Association of Clinical Endocrinologists 20th Annual Meeting; April 13–17, 2011; San Diego, CA
   Google Scholar
• . www.ClinicalTrials.gov. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI). http://clinicaltrials.gov/ct2/show/NCT01107886. Accessed April 23, 2012
   Google Scholar
• . www.ClinicalTrials.gov. CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT01243424. Accessed April 24, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Sitagliptin cardiovascular outcome study (0431-082 AM1): http://clinicaltrials.gov/ct2/show/NCT00790205. Accessed April 23, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Effects of saxagliptin on endothelial function (ESENDI). http://clinicaltrials.gov/ct2/show/NCT01319357. April 24, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Sitagliptin and kinetics of triglyceride-rich lipoproteins apolipoprotein B48 and B100 in patients with type 2 diabetes (JANUB48). http://clinicaltrials.gov/ct2/show/NCT01334229. Accessed April 23, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Effect of sitagliptin on postprandial lipoprotein metabolism. http://clinicaltrials.gov/ct2/show/NCT00939939. Accessed April 24, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Comparison of Risk of Major Cardiovascular Events Between Patients with Type 2 Diabetes Exposed to Saxagliptin and Those Exposed to Other Oral Antidiabetic Treatments. http://www.clinicaltrials.gov/ct2/show/NCT01086280?term=NCT01086280&rank=1. Accessed June 30, 2012
   Google Scholar
• . Beck—Nielsen H, Hother—Nielsen O, Pedersen O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med. 1988;5(7):613–620
   PubMedGoogle Scholar
• . Best JD, Judzewitsch RG, Pfeifer MA, Beard JC, Halter JB, Porte D Jr. The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes. Diabetes. 1982;31(4 pt 1):333–338
   PubMedGoogle Scholar
• . DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281–303
   PubMed Web of Science ®Google Scholar
• . Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321 (18):1231–1245
   PubMed Web of Science ®Google Scholar
• . Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15 (6):737–754
   PubMedGoogle Scholar
• . Aquilante CL. Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010;8(3):359–372
   PubMedGoogle Scholar
• . Zeggini E, McCarthy MI. TCF7 L2: the biggest story in diabetes genetics since HLA? Diabetologia. 2007;50(1):1–4
   PubMedGoogle Scholar
• . Cauchi S, El Achhab Y, Choquet H, . TCF7 L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med (Berl). 2007;85(7):777–782
   PubMed Web of Science ®Google Scholar
• . Wang J, Kuusisto J, Vänttinen M, . Variants of transcription factor 7-like 2 (TCF7 L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia. 2007;50(6):1192–1200
   PubMed Web of Science ®Google Scholar
• . Loos RJ, Franks PW, Francis RW, . TCF7 L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes. 2007;56(7):1943–1947
   PubMedGoogle Scholar
• . Pearson ER, Donnelly LA, Kimber C, . Variation in TCF7 L2 influences therapeutic response to sulfonylureas: a GoD-ARTs study. Diabetes. 2007;56(8):2178–2182
   PubMed Web of Science ®Google Scholar
• . Williams—Herman D, Swern AS, Davies MJ, Katzeff HL, Stein PP. In patients with type 2 diabetes, sitagliptin effectively lowers A1c regardless of patient age, gender, or body mass index. Diabetes. 2008;57( suppl 1):A148
   Google Scholar
• . Pratley RE, Rosenstock J, Pi—Sunyer FX, . Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30(12):3017–3022
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥ 75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13(1):55–64
   PubMed Web of Science ®Google Scholar
• . Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011;27(4):863–869
   PubMed Web of Science ®Google Scholar
• . Schernthaner G, Barnett AH, Emser A, . Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(5):470–478
   PubMed Web of Science ®Google Scholar
• . Esposito K, Cozzolino D, Bellastella G, . Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011;13(7):594–603
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27(3):309–317
   PubMed Web of Science ®Google Scholar
• . Prato SD, LaSalle J, Matthaei S, Bailey CJ; Global Partnership for Effective Diabetes Management. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2010; 64(3):295–304
   PubMedGoogle Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes—United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep. 2004;53(45):1066–1068
   PubMedGoogle Scholar
• . Prando R, Cheli V, Melga P, Giusti R, Ciuchi E, Odetti P. Is type 2 diabetes a different disease in obese and nonobese patients? Diabetes Care. 1998;21(10):1680–1685
   PubMedGoogle Scholar
• . Røder ME, Dinesen B, Hartling SG, . Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care. 1999;22(4):609–614
   PubMed Web of Science ®Google Scholar
• . Brunetti P. The lean patient with type 2 diabetes: characteristics and therapy challenge. Int J Clin Pract Suppl. 2007;153:3–9
   Google Scholar
• . Chang SA, Kim HS, Yoon KH, . Body mass index is the most important determining factor for the degree of insulin resistance in non-obese type 2 diabetic patients in Korea. Metabolism. 2004; 53(2):142–146
   PubMedGoogle Scholar
• . Taniguchi A, Fukushima M, Sakai M, . The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients. Metabolism. 2000;49(8):1001–1005
   PubMedGoogle Scholar
• . Kishimoto H, Taniguchi A, Fukushima M, . Effect of short-term low-intensity exercise on insulin sensitivity, insulin secretion, and glucose and lipid metabolism in non-obese Japanese type 2 diabetic patients. Horm Metab Res. 2002;34(1):27–31
   PubMedGoogle Scholar
• . Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab. 2009;11(12):1091–1099
   PubMedGoogle Scholar
• . Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011; 34(6):1431–1437
   PubMed Web of Science ®Google Scholar
• . Gibson TB, Song X, Alemayehu B, . Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010;16(8):589–600
   PubMed Web of Science ®Google Scholar
• . Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control. Manag Care. 2009;18(7):47–53
   PubMedGoogle Scholar
• . Fung V, Mangione CM, Huang J, . Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Serv Res. 2010; 45(2):355–375
   PubMed Web of Science ®Google Scholar
• . Hsu J, Fung V, Price M, . Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 2008;299(16):1929–1936
   PubMed Web of Science ®Google Scholar
• . Neuman P, Strollo MK, Guterman S, . Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Aff (Millwood). 2007;26(5):w630–s643
   PubMedGoogle Scholar
• . Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23(8):1311–1320
   PubMed Web of Science ®Google Scholar
• . Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res. 2002;30(1):71–79
   PubMed Web of Science ®Google Scholar
• . Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014–1029
   PubMed Web of Science ®Google Scholar
• . Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in type 2 diabetes: an opportunity to improve adherence and patient care. Diabet Med. 2010;27(7):739–743
   PubMedGoogle Scholar
• . Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–1224
   PubMed Web of Science ®Google Scholar
• . Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611–614
   PubMed Web of Science ®Google Scholar
• . Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30(10):1893–1907
   PubMed Web of Science ®Google Scholar
• . Holstein A, Seeringer A, Kovacs P. Therapy with oral antidiabetic drugs: applied pharmacogenetics. Br J Diabetes Vasc Dis. 2011;11:10–16
   Google Scholar
• . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6(2):133–156
   PubMed Web of Science ®Google Scholar
• . Evans JM, Ogston SA, Emslie—Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5):930–936
   PubMed Web of Science ®Google Scholar
• . Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002; 25(12):2244–2248
   PubMed Web of Science ®Google Scholar
• . Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010; 16(1):53–63
   PubMed Web of Science ®Google Scholar
• . Arnolds S, Dellweg S, Clair J, . Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509–1515
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Kipnes M, Luo E, ; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–745
   PubMed Web of Science ®Google Scholar
• . Rodriguez A, Reviriego J, Karamanos V, del Canizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study. Cardiovasc Diabetol. 2011;10:18
   PubMed Web of Science ®Google Scholar
• . Karamanos B, Thanopoulou A, Drossinos V, Charalampidou E, Sourmeli S, Archimandritis A; Hellenic ECLA Study Group. Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA). Curr Med Res Opin. 2011; 27(2):303–313
   PubMed Web of Science ®Google Scholar
• . Yang W, Chen L, Ji Q, . Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab. 2011;13(1):81–88
   PubMed Web of Science ®Google Scholar
• . Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–1406
   PubMed Web of Science ®Google Scholar
• . www.ClinicalTrials.gov. Risk of cardiovascular events in patients with type 2 diabetes initiating oral antidiabetic treatments. http://clinicaltrials.gov/ct2/show/NCT01086280. Accessed April 23, 2012
   Google Scholar
• . Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58(1):69–73
   PubMed Web of Science ®Google Scholar
• . Ogawa S, Ishiki M, Nako K, . Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223(2):133–135
   PubMedGoogle Scholar
• . Mistry GC, Maes AL, Lasseter KC, . Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592–598
   PubMed Web of Science ®Google Scholar
• . www.Drugs.com. Professional Drug Information database. Glimepiride prescribing information. Accessed November 3, 2011
   Google Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–2077
   PubMed Web of Science ®Google Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–494
   PubMed Web of Science ®Google Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM trial data. Diabetologia. 2004;47(6):969–975
   PubMed Web of Science ®Google Scholar
• . Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12
   PubMedGoogle Scholar
• . Koyasu M, Ishii H, Watarai M, . Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. Clin Ther. 2010;32(9): 1610–1617
   PubMed Web of Science ®Google Scholar
• . Oyama T, Saiki A, Endoh K, . Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. J Atheroscler Thromb. 2008;15(3):154–159
   PubMed Web of Science ®Google Scholar
• . Goldberg RB, Kendall DM, Deeg MA, ; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547–1554
   PubMed Web of Science ®Google Scholar
• . Wysham C, Lush C, Zhang B, Maier H, Wilhelm K. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(1):79–85
   PubMed Web of Science ®Google Scholar
• . Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975–1983
   PubMedGoogle Scholar
• . Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):1479–1484
   PubMed Web of Science ®Google Scholar
• . Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168(14):1531–1540
   PubMedGoogle Scholar